While Procept BioRobotics Corp has underperformed by -1.55%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PRCT fell by -10.98%, with highs and lows ranging from $103.81 to $47.04, whereas the simple moving average fell by -15.09% in the last 200 days.
On December 02, 2024, Morgan Stanley started tracking Procept BioRobotics Corp (NASDAQ: PRCT) recommending Overweight. A report published by Jefferies on November 14, 2024, Initiated its previous ‘Hold’ rating for PRCT. Piper Sandler also rated PRCT shares as ‘Overweight’, setting a target price of $42 on the company’s shares in an initiating report dated August 11, 2023. BTIG Research initiated its ‘Neutral’ rating for PRCT, as published in its report on October 31, 2022. Truist’s report from October 25, 2022 suggests a price prediction of $58 for PRCT shares, giving the stock a ‘Buy’ rating. Wells Fargo also rated the stock as ‘Overweight’.
Analysis of Procept BioRobotics Corp (PRCT)
Further, the quarter-over-quarter increase in sales is 55.28%, showing a positive trend in the upcoming months.
In order to gain a clear picture of Procept BioRobotics Corp’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of -27.62% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 7.74, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 994.13K can be a very valuable indicator of volatility for PRCT stock. On a monthly basis, the volatility of the stock is set at 3.09%, whereas on a weekly basis, it is put at 2.33%, with a loss of -5.98% over the past seven days. Furthermore, long-term investors anticipate a median target price of $78.33, showing growth from the present price of $61.16, which can serve as yet another indication of whether PRCT is worth investing in or should be passed over.
How Do You Analyze Procept BioRobotics Corp Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 5.24%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 91.65% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
PRCT shares are owned by institutional investors to the tune of 91.65% at present.
